Federal Register / Vol. 87, No. 88 / Friday, May 6, 2022 / Notices 27161 

states, territories, tribes and tribal 

organizations, area agencies on aging 

and service providers in delivering 

services under the Act. We also seek 

feedback on how OAA programs can 

advance equity, in alignment with 

Executive Order 13985 Advancing 

Racial Equity and Support for 

Underserved Communities Through the 

Federal Government. In this regard, 

please keep in mind the following: 

• All submissions will be considered 

and reviewed by ACL. 

• ACL seeks recommendations to 

address practical matters regarding 

regulations to implement the Older 

Americans Act, as reauthorized in 2020. 

(We may not be able to include all 

recommendations.) 

• If respondents have multiple 

recommendations, respondents may 

make multiple recommendations in the 

same submission. 

Submission Questions 

1. State the regulation for which the 

comment applies: 

a. 45 CFR part 1321—Grants to State 

and Community Programs on Aging; 

b. 45 CFR part 1322—Grants to Indian 

Tribes for Support and Nutrition 

Services; 

c. 45 CFR part 1323—Grants for 

Supportive and Nutritional Services to 

Older Hawaiian Natives; or 

d. 45 CFR part 1324 Allotments for 

Vulnerable Elder Rights Protection 

Activities, including Subpart A—State 

Long-Term Care Ombudsman Program. 

2. State the citation to which the 

comment applies, if applicable (for 

example, ‘‘45 CFR part 1321.1’’). 

3. State the nature of the comment: 

a. Deletion. 

b. Addition. 

c. Change. 

4. Provide detail on the reason for 

ACL to consider the comment for 

potential inclusion in a revision of 

Older Americans Act regulations. 

5. Provide detail on any benefits, 

including how equity will be advanced, 

and/or barriers that might result from 

incorporating the recommendation in a 

revision of Older Americans Act 

regulations. 

Please Note: This RFI is being issued 

for information and planning purposes 

only. It should not be construed as a 

solicitation or an obligation on the part 

of the federal government or the 

Administration for Community Living 

(ACL). ACL does not intend to issue any 

grant or contract awards based on 

responses to this invitation, or to 

otherwise pay for the preparation of any 

information submitted or for the 

government’s use of such information. 

ACL is not authorized to receive 

personally identifiable information (PII) 

through this RFI other than the contact 

information of the person submitting the 

information. Please do not include any 

PII in your submission. For example, do 

not include names, addresses, phone or 

Social Security numbers of any 

individuals. We will redact responses 

that contain PII. 

How the Information Will Be Used 

ACL is planning to update regulations 

for programs authorized under Titles III, 

VI, and VII of the Older Americans Act. 

The information gathered through this 

RFI will be used to inform ACL’s 

approach to updating these regulations. 

Background 

Congress passed the Older Americans 

Act (OAA) in 1965 in response to 

concern by policymakers about a lack of 

community social services for older 

persons. The original legislation 

established authority for grants to states 

for community planning and social 

services, research and development 

projects, and personnel training in the 

field of aging. The law also established 

the Administration on Aging (AoA) to 

administer the newly created grant 

programs and to serve as the federal 

focal point on matters concerning older 

persons. 

Although older individuals may 

receive services under many other 

federal programs, today the OAA is 

considered to be a major vehicle for the 

organization and delivery of social and 

nutrition services to this group and their 

caregivers. It authorizes a wide array of 

service programs through a national 

network of 56 state agencies on aging, 

618 area agencies on aging, nearly 

20,000 service providers, 281 Tribal 

organizations, representing 400 Tribes, 

and 1 Native Hawaiian organization. 

The OAA was most recently 

reauthorized on March 25, 2020. 

Dated: May 2, 2022. 

Alison Barkoff, 

Acting Assistant Secretary for Aging and 

Administrator, Administration for 

Community Living. 

Dated: May 2, 2022. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2022–09713 Filed 5–5–22; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–1998–P–0074] 

Grated Parmesan Cheese Deviating 

From Identity Standard; Amendment of 

Temporary Marketing Permit 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or we) is 

amending the temporary permit issued 

to Kraft Foods Inc. to market test a 

product designated as ‘‘100% Grated 

Parmesan Cheese’’ that deviates from 

the standards of identity for parmesan 

cheese and grated cheeses. Kraft Foods 

Inc.’s temporary permit is amended to 

identify Lactalis Heritage Dairy, Inc. 

(LHD) as the permit holder. This 

amendment will allow the permit 

holder to continue to test market the 

product and collect data on consumer 

acceptance. 

FOR FURTHER INFORMATION CONTACT: 

Marjan Morravej, Office of Nutrition and 

Food Labeling (HFS–820), Center for 

Food Safety and Applied Nutrition, 

Food and Drug Administration, 5001 

Campus Dr., College Park, MD 20740, 

240–402–2371; or Alexandra Jurewitz, 

Office of Regulations and Policy (HFS– 

024), Center for Food Safety and 

Applied Nutrition, Food and Drug 

Administration, 5001 Campus Dr., 

College Park, MD 20740, 240–402–2378. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of April 6, 1999 (64 FR 

16743), we issued a notice announcing 

that we had issued a temporary permit 

to Kraft Foods Inc. (now a part of Kraft 

Heinz, 200 East Randolph St., Suite 

7600, Chicago, IL 60601), to market test 

a product identified as ‘‘100% Grated 

Parmesan Cheese.’’ We issued the 

permit to facilitate market testing of a 

product that deviates from the 

requirements of the standard of identity 

for parmesan cheese (21 CFR 133.165) 

and grated cheeses (21 CFR 133.146) in 

that the product is formulated by using 

a different enzyme technology that fully 

cures the cheese in 6 months rather than 

10 months. 

In the Federal Register of December 

29, 2000 (65 FR 83040), we issued a 

notice announcing that we were 

extending the temporary market permit 

issued to Kraft Foods Inc. The extension 

allows the applicant to continue to 

measure consumer acceptance of the 

product and assess the commercial 

feasibility of the product, in support of 


JSPEARS on DSK121TN23PROD with NOTICES1
27162 Federal Register / Vol. 87, No. 88 / Friday, May 6, 2022 / Notices 

a petition to amend the standard of 

identity for parmesan cheese. The new 

expiration date of the permit will be 

either the effective date of a final rule 

amending the standard of identity for 

parmesan cheese that may result from 

the petition or 30 days after denial of 

the petition. 

In 2011, Kraft Foods Inc. spun off its 

North American grocery business to a 

new company called Kraft Foods Group. 

In 2015, Kraft Foods Group and H.J. 

Heinz Company merged to become Kraft 

Heinz. In September 2020, Kraft Heinz 

entered into an agreement to sell its 

natural, grated, cultured, and specialty 

cheese businesses in the United States, 

including its Kraft parmesan cheese 

business, to B.S.A. S.A., the parent 

company of the Lactalis Group (Lactalis) 

and its subsidiary, LHD. As of 

November 29, 2021, LHD has assumed 

responsibility for production and sale of 

all parmesan cheese subject to the 

temporary permit. 

Under our regulations at 21 CFR 

130.17(f), we are modifying the 

temporary permit issued to Kraft Foods 

Inc. for ‘‘100% Grated Parmesan 

Cheese’’ to identify LHD, 540 West 

Madison St., Suite 300, Chicago, IL 

60661, as the permit holder. All other 

conditions and terms of this permit 

remain the same. 

Dated: April 29, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–09750 Filed 5–5–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2007–D–0369] 

Product-Specific Guidance for 

Testosterone; Revised Draft Guidance 

for Industry; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a revised 

draft guidance for industry entitled 

‘‘Draft Guidance for Testosterone.’’ The 

revised draft guidance, when finalized, 

will provide product-specific 

recommendations on, among other 

things, the information and data needed 

to demonstrate bioequivalence (BE) to 

support abbreviated new drug 

applications (ANDAs) for testosterone 

pellet. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by July 5, 2022 to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2007–D–0369 for ‘‘Draft Guidance for 

Testosterone.’’ Received comments will 

be placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

You may submit comments on any 

guidance at any time (see 21 CFR 

10.115(g)(5)). 

Submit written requests for single 

copies of the draft guidance to the 

Division of Drug Information, Center for 

Drug Evaluation and Research, Food 

and Drug Administration, 10001 New 

Hampshire Ave., Hillandale Building, 

4th Floor, Silver Spring, MD 20993– 

0002. Send one self-addressed adhesive 

label to assist that office in processing 

your requests. See the SUPPLEMENTARY

INFORMATION section for electronic 

access to the draft guidance document. 

FOR FURTHER INFORMATION CONTACT: 

Christine Le, Center for Drug Evaluation 

and Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 75, Rm. 4714, Silver Spring, 

MD 20993–0002, 301–796–2398, PSGQuestions@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 


JSPEARS on DSK121TN23PROD with NOTICES1